KDR and gastric adenocarcinoma: As a highly selective vascular endothelial growth factor receptor-2 inhibitor, apatinib suppresses tumor angiogenesis by potently inhibiting VEGF-mediated signaling pathways critical for tumor neovascularization, enabling it clinical efficacy in patients with recurrent or progressive advanced gastric adenocarcinoma (32, 33).